Influenza Virus Vaccine for the 2011-2012 Season Announced
The Food and Drug Administration (FDA)'s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Bethesda, Md., on Feb. 25, 2011, to select the influenza viruses for the composition of the influenza vaccine for the 2011-2012 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2010-2011 vaccines, and the availability of candidate strains and reagents.
The committee recommended that vaccines to be used in the 2011-2012 influenza season in the U.S. contain the following:
- A/California/7/09 (H1N1)-like virus*
- A/Perth /16/2009 (H3N2)-like virus
- B/Brisbane/60/2008-like virus
*A/California/7/09 (H1N1)-like virus is the pandemic (H1N1) 2009 influenza virus
This years vaccine for the United States includes the same viruses that were used for the 2010-2011 influenza season and the influenza vaccine composition is identical to that recommended by the World Health Organization on Feb. 17, 2011, for the Northern Hemisphere's 2011-2012 influenza season.
-
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.
